Moat
Moat — MetLife, Inc. (MET)
1. Moat in One Page
Verdict: narrow moat. MetLife has two genuine, durable advantages — a scale-driven cost and distribution lead in U.S. Group Benefits (~23% share, 5+ percentage points of ROE over a single-line peer like Unum) and a capital- and regulator-gated co-leadership in Pension Risk Transfer (PRT) alongside Prudential. Around those two protected segments sits a portfolio that is good but not protected: Asia is a respectable foreign incumbent but does not out-earn the local giants; Latin America is contested by domestic and PE-backed entrants; MetLife Investment Management ($736B AUM post-PineBridge) is sub-scale next to PGIM ($1.6T) and Apollo/Blackstone/KKR; the legacy MetLife Holdings book (LTC + variable annuity run-off) is a value drag, not a moat. The 12.1% FY2025 ROE versus the 15–17% New Frontier target is the cleanest read on how much excess return the moat produces today: positive, but well below what a wide-moat franchise should deliver.
Two pieces of evidence make the narrow-moat case real, and one piece undermines it. Real: Group Benefits adjusted earnings grew +7.3% to $1.69B in FY2025 versus Unum's pure-group ROE of 6.7%, and PRT incumbency (~100 years, $5.5B/year of benefit administration to ~915,000 retirees) is a barrier no PE platform has yet replicated on jumbo deals. Undermining: the largest U.S. life premium-writers are mutuals (Northwestern Mutual, MassMutual, NY Life) — they have no shareholder ROE constraint, which means MetLife's retail life pricing power has a permanent ceiling that is structural, not cyclical.
Evidence Strength (0-100)
Durability (0-100)
Moat rating: Narrow. Weakest link: PE-platform spread compression and sub-scale MIM.
The right way to read this page. The Competition tab already mapped peers and threats. This tab does something different: it asks whether the things that look like advantages actually protect returns over a cycle, separates company-specific moat from industry attractiveness (insurance is regulated and capital-intensive, which protects everyone), and names what would make the moat fade. Where the conclusions overlap with Competition, that is corroboration, not duplication.
2. Sources of Advantage
The candidate moat sources, scored against evidence. "Proof quality" reflects whether the advantage shows up in numbers the market can verify (margin, share, retention, ROE), not in management adjectives.
A note on a moat we are not claiming. Network effects are absent — MetLife does not get more valuable to one customer because another customer joins. Patents are immaterial. Local route economics do not apply (this is not a parcel network). Calling those out matters because moat language is often loose; the moat here is scale + regulatory + distribution embedment, not "we have the brand" or "we are diversified."
3. Evidence the Moat Works
The moat must show up in the numbers — pricing, retention, share, returns, capital generation. Eight evidence items, drawn from filings and peer comparison. Some support the moat; some do not.
The clearest single chart of the moat-versus-no-moat question is the 5-year ROE band versus peers. Wide-moat insurers should deliver high, stable, mid-teens ROE. Narrow-moat insurers should deliver positive but cyclical ROE. No-moat insurers should print near-zero in any down year.
The MET line never went below 5%. PRU went negative. LNC was both the lowest (-12.5%) and the highest (43.2%) print in the set. AFL is the cleanest moat-like signature in the chart — high, stable, mid-teens — and is exactly what a wide-moat capital-light supplemental insurer should look like. MET sits in the middle: above the no-moat threshold, below the wide-moat threshold. That is the visual definition of "narrow."
4. Where the Moat Is Weak or Unproven
The moat is weakest where MetLife competes outside the two protected arenas. Five concrete weaknesses, ranked.
The single fragile assumption. The narrow-moat conclusion depends on MetLife retaining ~23% U.S. group share, jumbo PRT co-leadership with PRU, and Asia incumbency. If two of those three drift simultaneously — say group share drops below 22% and PE-backed reinsurers take meaningful jumbo PRT share — the moat case downgrades to "moat not proven" and the multiple compresses toward PRU's 1.21x book.
5. Moat vs Competitors
Each peer's moat looks different. Some are stronger on a specific axis; others are weaker overall but stronger in one product. Use this to triangulate where MetLife actually leads.
The chart says what the table implies: AFL is the closest thing to a wide moat in this peer set — high subjective moat score, mid-teens ROE, premium P/B — but its moat is narrow in scope (one product set, two countries). MET, PRU, and PFG cluster as narrow-moat composites at similar ROE levels. LNC and UNM are weaker (LNC for capital adequacy reasons, UNM for single-product concentration). The interesting investment question is not "does MET have a moat?" but "is MET's moat wide enough to deliver the New Frontier 15-17% ROE?"
6. Durability Under Stress
A moat only matters if it survives stress. MetLife has been stress-tested across the last cycle; some tests it passed, some are still pending.
The stress record reads like a narrow moat: bent but did not break in 2008-09, held in 2020 and 2022, has not yet been tested by sustained PE-platform encroachment or a major LTC update. The two pending stresses (PE-platform spread compression and LTC reserve adequacy) are the ones to underwrite skeptically.
7. Where MetLife, Inc. Fits
The moat is segment-specific, not enterprise-wide. The same balance sheet houses one wide-moat-shaped franchise, two narrow-moat-shaped franchises, two unprotected segments, and one option-value bet. Treating "MetLife" as a single moat misreads the company.
The moat-weighted earnings picture is helpful. Roughly 60% of FY2025 adjusted earnings come from segments with at least narrow-moat protection (Group, RIS, Asia = $5.07B of $6.43B operating segments) — but the remaining 40% (LatAm, EMEA, MIM, Corporate) is unprotected, sub-scale, or run-off. That mix is what drives the ROE-versus-target gap: the protected segments are doing what they should, but the unprotected segments dilute the headline.
8. What to Watch
Six signals that tell you whether MetLife's moat is widening, holding, or fading. Each is observable inside a quarter; together they answer the moat question better than any single ROE print.
The first moat signal to watch is the gap between MetLife's adjusted ROE and the 15-17% New Frontier target. Closing that gap is the cleanest proof the moat is producing excess returns; a sustained 3-point miss is the cleanest evidence it is not.